Skip to main content
. 2023 Dec 15;23(3):285–300. doi: 10.1158/1535-7163.MCT-23-0351

Figure 6.

Figure 6. OP-1250 shrinks ER+ breast cancer intracranial xenografts and prolongs animal survival. A, Schematic of intracranial xenograft experiment using ESR1Y537S ST941 PDX model. B, Representative intracranial MRIs from ST941-implanted vehicle and OP-1250-treated mice at indicated timepoints. Arrow indicates implantation site. C, Mean and SEM intracranial tumor volume over time with listed treatments as assessed by MRI in ST941 intracranial xenograft model. D, Percent change in intracranial tumor volume of individual animals in listed treatment groups at day 101 or last recorded timepoint of ST941 intracranial xenograft study, normalized to day 1 tumor volume. E, Kaplan–Meier graphs of animal survival over time in listed treatment groups of mice implanted intracranially with the ST941 PDX model. Dosing was ceased on day 100 of study, as indicated by the shaded area.

OP-1250 shrinks ER+ breast cancer intracranial xenografts and prolongs animal survival. A, Schematic of intracranial xenograft experiment using ESR1Y537S ST941 PDX model. B, Representative intracranial MRIs from ST941-implanted vehicle and OP-1250-treated mice at indicated timepoints. Arrow indicates implantation site. C, Mean and SEM intracranial tumor volume over time with listed treatments as assessed by MRI in ST941 intracranial xenograft model. D, Percent change in intracranial tumor volume of individual animals in listed treatment groups at day 101 or last recorded timepoint of ST941 intracranial xenograft study, normalized to day 1 tumor volume. E, Kaplan–Meier graphs of animal survival over time in listed treatment groups of mice implanted intracranially with the ST941 PDX model. Dosing was ceased on day 100 of study, as indicated by the shaded area.